S&P Futures
6,041.25 +3.00 (+0.05%) Dow Futures
44,993.00 +42.00 (+0.09%) Nasdaq Futures
20,992.50 -1.00 (-0.00%) Russell 2000 Futures
2,437.80 +5.40 (+0.22%) Crude Oil
68.63 -0.14 (-0.20%) Gold
2,629.40 +8.10 (+0.31%)
Coya Therapeutics, Inc. (COYA)
| Previous Close | 6.50 |
| Open | 6.50 |
| Bid | 6.29 x 100 |
| Ask | 6.62 x 100 |
| Day's Range | 6.34 - 6.91 |
| 52 Week Range | 4.75 - 10.69 |
| Volume | |
| Avg. Volume | 78,358 |
| Market Cap | 106.593M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- TipRanks
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
Coya Therapeutics, Inc. ( (COYA) ) has issued an update. Coya Therapeutics announced positive results from a Phase 2 trial of low-dose interleukin-2 (LD IL-2) in Alzheimer’s patients, showing safety and cognitive stabilization benefits with the q4wks regimen. The trial highlighted significant improvements in biomarkers and cognitive function, supporting Treg modulation strategies for neurodegenerative diseases. The findings bolster confidence in advancing LD IL-2 treatments and potential combina
- Benzinga
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24). The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s. Also Read: EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Dis
